Skip to content

Study · Observational study · n = 102,590 · 2026

5 results

Ocular Outcomes with Tirzepatide versus Glucagon-like Peptide-1 Receptor Agonists in Type 2 Diabetes.

Hong AT, Lin F, Keenan JD, Stewart JM

Ophthalmology. Retina6 Feb 2026Cited by 1 (Europe PMC)

PMID41655764 (opens in a new tab)DOI10.1016/j.oret.2026.02.002 (opens in a new tab)PepBankPUB-41655764
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, tirzepatide was associated with a lower risk of diabetic retinopathy than non-GIP GLP-1 receptor agonists (HR 0.79).

    In plain wordsIn adults with type 2 diabetes, tirzepatide was linked to a lower risk of diabetic eye disease than GLP-1 drugs without GIP activity.

    Peptide
    Tirzepatide
    Outcome
    DecreaseDiabetic retinopathy
    Study

    n = 102,590

    Comparator
    Non-GIP GLP-1 receptor agonists
    Outcome group
    Vision and retina · Eye
    Studied dose
    Dose not stated

    Measurements

    Hazard ratio
    0.79 HR
    diabetic retinopathy

    Source sentences

    Summary
    Tirzepatide use was associated with decreased risk of DR (HR, 0.79; 95% confidence interval [CI], 0.72-0.87)
    2 context sentences
    Summary · context
    Adults with T2D initiating tirzepatide or a non-GIP GLP-1 RA, with no prior use of either drug class.
    Summary · context
    A cohort of patients initiating therapy with tirzepatide was compared with another cohort initiating a non-GIP GLP-1 RA.
  2. 02HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, tirzepatide was associated with a lower risk of diabetic macular edema than non-GIP GLP-1 receptor agonists (HR 0.82).

    In plain wordsIn adults with type 2 diabetes, tirzepatide was linked to a lower risk of macular swelling than GLP-1 drugs without GIP activity.

    Peptide
    Tirzepatide
    Outcome
    DecreaseDiabetic macular edema
    Study

    n = 102,590

    Comparator
    Non-GIP GLP-1 receptor agonists
    Outcome group
    Vision and retina · Eye
    Studied dose
    Dose not stated

    Measurements

    Hazard ratio
    0.82 HR
    diabetic macular edema

    Source sentences

    Summary
    DME (HR, 0.82; 95% CI, 0.68-0.96)
    2 context sentences
    Summary · context
    Adults with T2D initiating tirzepatide or a non-GIP GLP-1 RA, with no prior use of either drug class.
    Summary · context
    A cohort of patients initiating therapy with tirzepatide was compared with another cohort initiating a non-GIP GLP-1 RA.
  3. 03HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, tirzepatide was associated with a lower risk of vitreous hemorrhage or retinal detachment than non-GIP GLP-1 receptor agonists.

    In plain wordsIn adults with type 2 diabetes, tirzepatide was linked to lower risk of eye bleeding or retinal detachment than GLP-1 drugs without GIP.

    Peptide
    Tirzepatide
    Outcome
    DecreaseVitreous hemorrhage or retinal detachment
    Study

    n = 102,590

    Comparator
    Non-GIP GLP-1 receptor agonists
    Outcome group
    Vision and retina · Eye
    Studied dose
    Dose not stated

    Source sentences

    Summary
    VH/RD (HR, 066; 95% CI, 0.45-0.95)
    2 context sentences
    Summary · context
    Adults with T2D initiating tirzepatide or a non-GIP GLP-1 RA, with no prior use of either drug class.
    Summary · context
    A cohort of patients initiating therapy with tirzepatide was compared with another cohort initiating a non-GIP GLP-1 RA.
  4. 04HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, tirzepatide was associated with a lower risk of diabetic retinopathy-related vision-saving interventions than non-GIP GLP-1 receptor agonists (HR 0.65).

    In plain wordsIn adults with type 2 diabetes, tirzepatide was linked to fewer sight-saving eye treatments than GLP-1 drugs without GIP activity.

    Peptide
    Tirzepatide
    Outcome
    DecreaseDR-related vision-saving interventions
    Study

    n = 102,590

    Comparator
    Non-GIP GLP-1 receptor agonists
    Outcome group
    Vision and retina · Eye
    Studied dose
    Dose not stated

    Measurements

    Hazard ratio
    0.65 HR
    DR-related vision-saving interventions

    Source sentences

    Summary
    DR-related vision-saving interventions (HR, 0.65; 95% CI, 0.49-0.88)
    2 context sentences
    Summary · context
    Adults with T2D initiating tirzepatide or a non-GIP GLP-1 RA, with no prior use of either drug class.
    Summary · context
    A cohort of patients initiating therapy with tirzepatide was compared with another cohort initiating a non-GIP GLP-1 RA.
  5. 05HumanObservational studySafety outcome

    In adults with type 2 diabetes, tirzepatide was associated with a lower risk of NAION than non-GIP GLP-1 receptor agonists (HR 0.45).

    In plain wordsIn adults with type 2 diabetes, tirzepatide was linked to a lower risk of one type of optic nerve damage than GLP-1 drugs without GIP.

    Peptide
    Tirzepatide
    Outcome
    DecreaseNonarteritic anterior ischemic optic neuropathy
    Study

    n = 102,590

    Comparator
    Non-GIP GLP-1 receptor agonists
    Outcome group
    Vision and retina · Eye
    Studied dose
    Dose not stated

    Measurements

    Hazard ratio
    0.45 HR
    NAION

    Source sentences

    Summary
    NAION (HR, 0.45; 95% CI, 0.27-0.86) compared with non-GIP GLP-1 RA use.
    2 context sentences
    Summary · context
    Adults with T2D initiating tirzepatide or a non-GIP GLP-1 RA, with no prior use of either drug class.
    Summary · context
    A cohort of patients initiating therapy with tirzepatide was compared with another cohort initiating a non-GIP GLP-1 RA.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:07 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.